CN1163485C - 氨氯地平系列盐及其制备方法和用途 - Google Patents
氨氯地平系列盐及其制备方法和用途 Download PDFInfo
- Publication number
- CN1163485C CN1163485C CNB00124812XA CN00124812A CN1163485C CN 1163485 C CN1163485 C CN 1163485C CN B00124812X A CNB00124812X A CN B00124812XA CN 00124812 A CN00124812 A CN 00124812A CN 1163485 C CN1163485 C CN 1163485C
- Authority
- CN
- China
- Prior art keywords
- amlodipine
- acid
- salts
- preparation
- dissolved
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 150000003839 salts Chemical class 0.000 title claims abstract description 22
- 238000000034 method Methods 0.000 title abstract 3
- 229960000528 amlodipine Drugs 0.000 claims abstract description 55
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 claims abstract description 44
- 239000002253 acid Substances 0.000 claims abstract description 15
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims abstract description 12
- JXTHNDFMNIQAHM-UHFFFAOYSA-N dichloroacetic acid Chemical compound OC(=O)C(Cl)Cl JXTHNDFMNIQAHM-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000002904 solvent Substances 0.000 claims abstract description 10
- 235000001968 nicotinic acid Nutrition 0.000 claims abstract description 9
- 239000011664 nicotinic acid Substances 0.000 claims abstract description 9
- 239000003814 drug Substances 0.000 claims abstract description 8
- 229940114081 cinnamate Drugs 0.000 claims abstract description 6
- 229940120124 dichloroacetate Drugs 0.000 claims abstract description 6
- WBYWAXJHAXSJNI-VOTSOKGWSA-M trans-cinnamate Chemical compound [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 claims abstract description 6
- BGXVCBNVNUORTP-UHFFFAOYSA-N OC(=O)CCCCC(O)=O.CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl Chemical compound OC(=O)CCCCC(O)=O.CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl BGXVCBNVNUORTP-UHFFFAOYSA-N 0.000 claims abstract description 5
- XRHGYUZYPHTUJZ-UHFFFAOYSA-N 4-chlorobenzoic acid Chemical compound OC(=O)C1=CC=C(Cl)C=C1 XRHGYUZYPHTUJZ-UHFFFAOYSA-N 0.000 claims abstract description 4
- 206010020772 Hypertension Diseases 0.000 claims abstract description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical group CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 24
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 18
- 238000003756 stirring Methods 0.000 claims description 16
- 238000002360 preparation method Methods 0.000 claims description 15
- -1 amlodipine Chlorodracylic acid salt Chemical class 0.000 claims description 12
- 238000002425 crystallisation Methods 0.000 claims description 8
- 230000008025 crystallization Effects 0.000 claims description 8
- HTIQEAQVCYTUBX-KRWDZBQOSA-N (S)-amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-KRWDZBQOSA-N 0.000 claims description 5
- BBYDXOIZLAWGSL-UHFFFAOYSA-N 4-fluorobenzoic acid Chemical compound OC(=O)C1=CC=C(F)C=C1 BBYDXOIZLAWGSL-UHFFFAOYSA-N 0.000 claims description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 4
- 229960000935 dehydrated alcohol Drugs 0.000 claims description 4
- 239000003960 organic solvent Substances 0.000 claims description 4
- NQBWNECTZUOWID-UHFFFAOYSA-N (E)-cinnamyl (E)-cinnamate Natural products C=1C=CC=CC=1C=CC(=O)OCC=CC1=CC=CC=C1 NQBWNECTZUOWID-UHFFFAOYSA-N 0.000 claims description 3
- NQBWNECTZUOWID-QSYVVUFSSA-N cinnamyl cinnamate Chemical compound C=1C=CC=CC=1\C=C/C(=O)OC\C=C\C1=CC=CC=C1 NQBWNECTZUOWID-QSYVVUFSSA-N 0.000 claims description 3
- 229960005215 dichloroacetic acid Drugs 0.000 claims description 3
- 230000000302 ischemic effect Effects 0.000 claims description 3
- 229960003512 nicotinic acid Drugs 0.000 claims description 3
- 230000002792 vascular Effects 0.000 claims description 3
- 239000012467 final product Substances 0.000 claims description 2
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 239000000460 chlorine Substances 0.000 claims 1
- 229950009366 flordipine Drugs 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract description 3
- BBYDXOIZLAWGSL-UHFFFAOYSA-M 4-fluorobenzoate Chemical compound [O-]C(=O)C1=CC=C(F)C=C1 BBYDXOIZLAWGSL-UHFFFAOYSA-M 0.000 abstract 1
- 150000007513 acids Chemical class 0.000 abstract 1
- 239000013078 crystal Substances 0.000 abstract 1
- 230000002349 favourable effect Effects 0.000 abstract 1
- 238000001914 filtration Methods 0.000 abstract 1
- 208000028867 ischemia Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 235000019439 ethyl acetate Nutrition 0.000 description 7
- 239000000126 substance Substances 0.000 description 3
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- TZNOWAJJWCGILX-BTJKTKAUSA-N (z)-but-2-enedioic acid;3-o-ethyl 5-o-methyl 2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound OC(=O)\C=C/C(O)=O.CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl TZNOWAJJWCGILX-BTJKTKAUSA-N 0.000 description 1
- 206010003225 Arteriospasm coronary Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 108090000312 Calcium Channels Proteins 0.000 description 1
- 102000003922 Calcium Channels Human genes 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 208000003890 Coronary Vasospasm Diseases 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- ZPBWCRDSRKPIDG-UHFFFAOYSA-N amlodipine benzenesulfonate Chemical compound OS(=O)(=O)C1=CC=CC=C1.CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl ZPBWCRDSRKPIDG-UHFFFAOYSA-N 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 210000002565 arteriole Anatomy 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 201000011634 coronary artery vasospasm Diseases 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明为氨氯地平系列盐及其制备方法和用途。包括氨氯地平二氯乙酸盐、氨氯地平对氯苯甲酸盐、氨氯地平对氟苯甲酸盐、氨氯地平肉桂酸盐、氨氯地平烟酸盐和氨氯地平己二酸盐；制备时在常温下，将溶于溶剂的氨氯地平与酸充分搅拌，过滤得结晶即可。本发明的氨氯地平系列盐制备方法科学合理，简单易行，所制产品稳定性好、生理作用强，具有良好的药物可接受性、合适的理化性质，更适合用于药物配方，主要用于治疗缺血及高血压症。
Description
技术领域
本发明涉及医药领域，特别是一种氨氯地平系列盐及其制备方法和用途。
背景技术
氨氯地平(Amlodpine)
英文化学名：3-ethyl-5-methyl(±)2[(2-aminoethoxyl)methyl]-4-(2-chlorophenyl)1.4dihydro-6-methyl-3.5-pyridine di-carbonylate
中文化学名：3-乙基-5-甲基-2-(2-氨乙氧甲基)-4-(2氯苯基)-1.4二氢-6-甲基-3.5-吡啶二羧酸酯
结构式：
分子式：C20H25N2O5CI
分子量：409.1
氨氯地平是一种长效钙内流阻滞剂，阻滞心肌和血管平滑肌细胞外钙离子经细胞膜的钙离子通道进入细胞，直接舒张血管平滑肌，扩张外周小动脉、扩张冠状动脉、解除冠状动脉痉挛绞通的作用。美国pfizer公司在欧洲专利EP89167及美国专利US4.572.909中公布了氨氯地平及其氨氯地平草酸盐、马来酸盐、盐酸盐、氢溴酸盐、硫酸盐、磷酸盐、柠檬酸盐及葡萄糖酸盐的制备方法，并认为氨氯地平马来酸盐较为理想。在美国专利US4.879.303中又推荐氨氯地平苯磺酸盐，认为该盐更适合于制备氨氯地平的加成盐用于药物配方中。
发明内容
本发明的一个目的是提供另外几种氨氯地平系列盐，包括氨氯地平二氯乙酸盐、氨氯地平对氯苯甲酸盐、氨氯地平对氟苯甲酸盐、氨氯地平肉桂酸盐、氨氯地平烟酸盐和氨氯地平己二酸盐。
本发明的另一个目的是提供一种上述氨氯地平系列盐的制备方法。
本发明还有一个目的是提供一种上述氨氯地平系列盐的用途。
本发明的氨氯地平系列盐包括氨氯地平二氯乙酸盐、氨氯地平对氯苯甲酸盐、氨氯地平对氟苯甲酸盐、氨氯地平肉桂酸盐、氨氯地平烟酸盐和氨氯地平己二酸盐；所述这六种盐均具有良好的药物可接受性、合适的理化性质，更适合用于药物配方，主要用于治疗缺血及高血压症；尤其是氨氯地平对氟苯甲酸盐稳定性好，生理作用强，可提高其生物利用度。
所述氨氯地平六种盐的理化常数及分析结果列于表1.其结构式如下：
表1.氨氯地平六种盐的理化常数及分析结果
本发明的氨氯地平系列盐的制备方法包括在常温下，将氨氯地平溶于少量有机溶剂中，搅拌下滴加入已溶于同一溶剂的酸，搅拌1-2小时，过滤得结晶即可。
其中，所述有机溶剂可为乙酸乙酯、无水乙醚和无水乙醇。
所述酸为二氯乙酸、对氯苯甲酸、对氟苯甲酸、肉桂酸、烟酸和己二酸。
所述氨氯地平∶酸∶溶剂＝1∶1.0-1.5∶50-100重量份数。
本发明的氨氯地平系列盐进一步增加了氨氯地平系列盐的品种数量，制备方法科学合理，简单易行，所制产品稳定性好、生理作用强，具有良好的药物可接受性、合适的理化性质，更适合用于药物配方，主要用于治疗缺血及高血压症。
下面结合实施例进一步描述本发明。
具体实施方式
实施例1.
氨氯地平二氯乙酸盐制备：
将新鲜制得的氨氯地平溶于部分乙酸乙酯中，搅拌下滴加入溶于乙酸酯的二氯乙酸溶液，室温搅拌2小时，过滤得结晶，熔点：141-143℃。
其中，氨氯地平∶酸∶溶剂-1∶1.2∶80重量份数。
实施例2
氨氯地平对氯苯甲酸盐的制备：
将新鲜制得的氨氯地平溶于部分乙酸乙酯中，搅拌下滴加入溶于乙酸乙酯的对氯苯甲酸溶液，室温搅拌2小时，过滤得结晶，溶点：157-159℃。
其中，氨氯地平∶酸∶溶剂＝1∶1.2∶80重量份数。
实施例3.
氨氯地平对氟苯甲酸盐的制备：
将新鲜制得的氨氯地平溶于部分无水乙醚中，搅拌下滴加入溶于无水乙醚的对氟苯甲酸溶液，室温搅拌1小时，过滤得结晶，溶点：96-98℃。
其中，氨氯地平∶酸∶溶剂＝1∶1.2∶80重量份数。
实施例4.
氨氯地平肉桂酸盐的制备：
将新鲜制得的氨氯地平溶于部分无水乙醚中，搅拌下滴加入溶于无水乙醚的肉桂酸溶液，室温搅拌1小时，过滤得结晶，熔点：116-118℃。
其中，氨氯地平∶酸∶溶剂＝1∶1.2∶80重量份数。
实施例5.
氨氯地平烟酸盐的制备：
将新鲜制得的氨氯地平溶于部分无水乙醇中，搅拌下滴加入溶于无水乙醇的烟酸溶液，室温搅拌2小时，过滤得结晶，溶点：167-169℃。
其中，氨氯地平∶酸∶溶剂＝1∶1.2∶80重量份数。
实施例6
氨氯地平己二酸盐的制备：
将新鲜制得的氨氯地平溶于部分乙酸乙酯中，搅拌下，滴加入溶于乙酸乙酯的己二酸溶液，室温搅拌2小时，过滤得结晶，熔点：160-162℃。
其中，氨氯地平∶酸∶溶剂＝1∶1.2∶80重量份数。
Claims (5)
1、氨氯地平系列盐，选自氨氯地平二氯乙酸盐、氨氯地平对氯苯甲酸盐、氨氯地平对氟苯甲酸盐、氨氯地平肉桂酸盐、氨氯地平烟酸盐和氯氯地平已二酸盐。
2、一种如权利要求1所述的氨氯地平系列盐的制备方法，其特征是在常温下，将氨氯地平溶于少量有机溶剂中，搅拌下滴加入已溶于同一溶剂的酸，搅拌1-2小时，过滤得结晶即可；
其中，所述的酸为二氯乙酸、对氯苯甲酸、对氟苯甲酸、肉桂酸、烟酸或己二酸。
3、如权利要求2所述的制备方法，其特征是所述有机溶剂为乙酸乙酯、无水乙醚或无水乙醇。
4、如权利要求2所述的制备方法，其特征是所述氨氯地平∶酸∶溶剂＝1∶1.0-1.5∶50-100重量份数。
5、一种氨氯地平系列盐，选自氨氯地平二氯乙酸盐、氨氯地平对氯苯甲酸盐、氨氯地平对氟苯甲酸盐、氨氯地平肉桂酸盐、氨氯地平烟酸盐和氨氯地平己二酸盐在制备治疗缺血及高血压症药物中的应用。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB00124812XA CN1163485C (zh) | 2000-09-15 | 2000-09-15 | 氨氯地平系列盐及其制备方法和用途 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB00124812XA CN1163485C (zh) | 2000-09-15 | 2000-09-15 | 氨氯地平系列盐及其制备方法和用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1343663A CN1343663A (zh) | 2002-04-10 |
| CN1163485C true CN1163485C (zh) | 2004-08-25 |
Family
ID=4590678
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB00124812XA Expired - Fee Related CN1163485C (zh) | 2000-09-15 | 2000-09-15 | 氨氯地平系列盐及其制备方法和用途 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1163485C (zh) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070135488A1 (en) | 2002-04-13 | 2007-06-14 | Chung You S | Amlodipine nicotinate and process for the preparation thereof |
| KR100496436B1 (ko) * | 2002-07-30 | 2005-06-20 | 씨제이 주식회사 | 암로디핀의 유기산염 |
| JP4319148B2 (ja) * | 2002-09-11 | 2009-08-26 | ハンリム ファーマシューティカル カンパニー リミテッド | Ｓ−（−）−アムロジピンニコチネート及びその製造方法 |
| AU2003253460A1 (en) * | 2002-09-19 | 2004-04-08 | Cj Corporation | Crystalline organic acid salt of amlodipine |
| WO2005042485A1 (en) * | 2003-10-30 | 2005-05-12 | Sk Chemicals, Co., Ltd. | Acid added salts of amlodipine |
| KR100830003B1 (ko) * | 2006-10-31 | 2008-05-15 | 씨제이제일제당 (주) | 결정성 ｓ-(-)-암로디핀 아디핀산 염 무수물 및 이의 제조방법 |
| KR100843401B1 (ko) * | 2006-12-04 | 2008-07-04 | 씨제이제일제당 (주) | 결정성 ｓ-(-)-암로디핀 캠실레이트 무수물 및 이의제조방법 |
-
2000
- 2000-09-15 CN CNB00124812XA patent/CN1163485C/zh not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1343663A (zh) | 2002-04-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0244944B1 (en) | Salts of amlodipine | |
| DE69814069T2 (de) | Neuartige form von s-omeprazol | |
| DE69720774T2 (de) | S-omeprazol in festform | |
| KR100452491B1 (ko) | 신규한 결정형 암로디핀 캠실레이트 염 및 그의 제조방법 | |
| CN1049428C (zh) | 短效的二氢吡啶类化合物及其制备方法和用途 | |
| CN1030422A (zh) | 9-去氧-9a-氮杂-9a-甲基-9a-高红霉素A二水合物 | |
| CN1163485C (zh) | 氨氯地平系列盐及其制备方法和用途 | |
| AU661483B2 (en) | Crystalline tiagabine hydrochloride monohydrate, its preparation and use | |
| CN1101810C (zh) | 盐酸乐卡地平的制备方法 | |
| WO2008060093A1 (en) | Crystalline s-(-)-amlodipine maleic acid salt anhydride and preparation method thereof | |
| KR101123018B1 (ko) | 결정화를 통한 목시덱틴의 정제 방법 | |
| KR19990076972A (ko) | 신규한 제조 방법 | |
| DE60116514T2 (de) | Amlodipinhemimaleat | |
| EP1499592A1 (en) | Amlodipine nicotinate and process for the preparation thereof | |
| DE69917282T2 (de) | Verfahren zur herstellung von zofenopril-calciumsalz | |
| CN1046901A (zh) | 1，5-苯并硫氮杂衍生物的制备方法 | |
| CA2624934C (en) | Preparing method for amorphous lercanidipine | |
| US20100216838A1 (en) | Fexofenadine base polymorphic forms | |
| DE60312953T2 (de) | Stabiles lansoprazol, enthaltend mehr als 500 ppm bis zu 3000 ppm wasser und mehr als 200 ppm bis zu 5000 ppm alkohol | |
| WO2008069469A1 (en) | Crystalline s-(-)-amlodipine camsylate anhydride and preparation method thereof | |
| CN102382169A (zh) | 阿加曲班单一立体异构体的分离方法及多晶型物 | |
| CN1489578A (zh) | 3-(3-脒苯基)-5-[({[1-(1-亚氨基乙基)-4-哌啶基]甲基}氨基)甲基]苯甲酸二盐酸盐及其制备方法 | |
| CN110615757B (zh) | 一种二氢吡啶类化合物的制备方法 | |
| CN1044455A (zh) | 2，2，-二(1，6，7-三羟基-3-甲基-5-异丙基-8-萘甲醛)的纯化方法 | |
| WO2008054096A1 (en) | Crystalline s-(-)-amlodipine adipic acid salt anhydrous and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: BEIJING RUIKANG MEDICINE TECHN CO., LTD. Free format text: FORMER OWNER: FU JUNCHANG Effective date: 20111103 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20111103 Address after: 100070 room 8, No. 106, Feng Feng Road, Fengtai District Science City, Beijing Patentee after: Beijing Ruikang Medicine Techn Co., Ltd. Address before: 100070, room 8, No. 106, Feng Feng Road, Fengtai Science City, Beijing Patentee before: Fu Junchang |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20040825 Termination date: 20180915 |